
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson's pharmaceutical division is demonstrating significant potential for growth, particularly with icotrokinra, which has achieved a notable 30.2% clinical remission rate compared to 11.1% for the placebo, reinforcing its position as a transformative asset in the immunology pipeline. The management anticipates over $5 billion in annual peak sales for icotrokinra, driven by its efficacy, safety profile, and convenience of administration, indicating a strong strategic outlook in addressing unmet needs within the inflammatory bowel disease (IBD) and psoriasis markets. Additionally, the company's manufacturing capabilities and competitive edge in a crowded market further enhance the potential for robust financial performance moving forward.
Bears say
Johnson & Johnson's recent divestment of its consumer business, Kenvue, in 2023 eliminates a diversified revenue stream, concentrating all sales into its pharmaceutical and medical device divisions. This shift, along with the company's heavy reliance on the U.S. market, where over half of its revenue is generated, exposes it to potential regulatory and market risks inherent in the domestic landscape. Additionally, ongoing challenges within the pharmaceutical division's therapeutic areas may lead to future revenue volatility, dampening investor confidence in the stock's stability.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares